SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Idorsia to Advance Daridorexant Development in Autism Spectrum Disorder

Idorsia said findings from a Phase 2 pediatric insomnia study support advancing daridorexant development in autism spectrum disorder.

IDIA

Related stories